Aurobindo Pharma


'Aurobindo Pharma' - 16 Video Result(s)

'Aurobindo Pharma' - 295 News Result(s)

  • Aurobindo Pharma Gains On Buzz Of Big UK Acquisition

    Aurobindo Pharma Gains On Buzz Of Big UK Acquisition

    Aurobindo Pharma shares gained over 1 per cent on Monday after a news report said that the Indian pharma company is a frontrunner to buy Teva Pharmaceutical's UK business, which had revenue of around $300 million last fiscal.

  • Buy JK Tyre, Castrol India, Reliance Capital: Pradip Hotchandani

    Buy JK Tyre, Castrol India, Reliance Capital: Pradip Hotchandani

    Pradip Hotchandani is bullish on Tata Motors, EIL, Reliance Capital, JK Tyre & Industries, Castrol India and India Cements.

  • Sensex Ends 70 Points Higher, Aurobindo Pharma Surges 7% On Q1

    Sensex Ends 70 Points Higher, Aurobindo Pharma Surges 7% On Q1

    Sensex and Nifty ended higher on Wednesday led by gains in drug maker Aurobindo Pharma which posted stellar June quarter numbers but sentiment remained edgy as investors awaited further clues on whether the Federal Reserve will raise U.S. interest rates this year.

  • Aurobindo Pharma Shares Soar Over 7% On Q1 Earnings, Debt Reduction

    Aurobindo Pharma Shares Soar Over 7% On Q1 Earnings, Debt Reduction

    Aurobindo Pharma shares jumped over 5 per cent on Wednesday, following the drugmaker's Q1 earnings announcement yesterday. Aurobindo Pharma was the top gainer in the Nifty50 index.

  • Sensex Rises Nearly 100 Points; Infosys Among Top Movers

    Sensex Rises Nearly 100 Points; Infosys Among Top Movers

    Indian stock markets are likely to open lower on Wednesday, tracking weakness in Asian equities. The Nifty futures on Singapore Exchange traded 26 points or 0.30 per cent lower at 8,628 as of 08.30 a.m., indicating a weak start for Sensex and Nifty.

  • Aurobindo Pharma Q1 Net Jumps 24% To Rs 585 Crore

    Aurobindo Pharma Q1 Net Jumps 24% To Rs 585 Crore

    Drug firm Aurobindo Pharma on Tuesday reported a 23.81 per cent rise in consolidated net profit to Rs 584.96 crore for the first quarter ended June 30, 2016, mainly on account of robust sales.

  • Buy Bank Of Baroda, Aurobindo Pharma; Avoid Idea Cellular: Sumeet Bagadia

    Buy Bank Of Baroda, Aurobindo Pharma; Avoid Idea Cellular: Sumeet Bagadia

    Investors should buy Nifty around 8,620-8,630 with stop loss at 8,580 for target of 8,700-8,730 in a day or two, says Sumeet Bagadia, associate director at Choice Broking.

  • Aurobindo Pharma To Set Up Vaccine Manufacturing Facility

    Aurobindo Pharma To Set Up Vaccine Manufacturing Facility

    Drug maker Aurobindo Pharma will set up a facility to manufacture 50 million dosages of vaccines per annum as it plans to launch its vaccine products commercially in 2018.

  • Aurobindo Pharma Gets US Regulator's Nod For Anti-Infective Injection

    Aurobindo Pharma Gets US Regulator's Nod For Anti-Infective Injection

    Aurobindo Pharma has received approval from the US health regulator to make and market its anti-infective Linezolid injection in the American market.

  • Buy Tata Motors, Dish TV, Sell United Spirits: Ruchit Jain

    Buy Tata Motors, Dish TV, Sell United Spirits: Ruchit Jain

    The BSE Sensex snapped a four-day losing streak on Thursday amid strong buying by foreign investors. Many analysts expect markets to correct, following the passage of the GST bill in Rajya Sabha

  • Dr Reddy's, Cipla, Aurobindo Among Others To Buy Products From Teva

    Dr Reddy's, Cipla, Aurobindo Among Others To Buy Products From Teva

    Dr Reddy's laboratories, Cipla and Aurobindo Pharma are among 11 firms that may acquire 79 existing and future drugs from Teva Pharmaceuticals as part of the condition set by the US Federal Trade Commission for $40.5 billion Teva-Allegran deal.

  • Buy Tata Power, BHEL; Sell HCL Tech: Sumeet Jain

    Buy Tata Power, BHEL; Sell HCL Tech: Sumeet Jain

    The Nifty faces stiff resistance around 8,600-8,620 and fresh buying is unlikely to emerge unless the benchmark takes out these levels, says Sumeet Jain, head - derivatives & technicals with Destimoney Securities. Nifty is likely to see expiry below 8,450 for this month's contract, he added.

  • Sensex Ends Over 100 Points Higher On Buying In Pharma Shares

    Sensex Ends Over 100 Points Higher On Buying In Pharma Shares

    Indian shares rose on Wednesday on the back of broad-based buying while pharma stocks outperformed as drug makers such as Glenmark Pharmaceuticals and Aurobindo Pharma gained after getting approvals for generic versions of a blockbuster cholesterol drug in the U.S.

  • Aurobindo Pharma Surges 4% On US Approval For Cholesterol Drug

    Aurobindo Pharma Surges 4% On US Approval For Cholesterol Drug

    Aurobindo Pharma surged nearly 4 per cent to Rs 788 today after the drugmaker launched the Rosuvastatin Calcium Tablets in the US following approval from the American drug regulator.

  • Sensex Rises Over 100 Points Led By Gains In HDFC Bank, ITC

    Sensex Rises Over 100 Points Led By Gains In HDFC Bank, ITC

    The BSE Sensex rose over 100 points on Wednesday, while the broader Nifty traded above the key 8,550 levels. Indian stock markets outperformed Asian equities that traded with a mixed bias today.

................................ Advertisement ................................

................................ Advertisement ................................